Maraviroc

马拉韦罗

Report date: 2026/03/17 15:13:37
NMEFirst In Class

Base Information

Drug NameMaraviroc
Drug Alias Name玛雷韦洛Maravirocum马拉维若马拉维诺马拉韦若 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC-C chemokine receptor type 5 antagonists
TargetsC-C chemokine receptor type 5
Therapy Area/IndicationsRejection of lung transplantationCoronavirus Disease 2019 (COVID-19)Ischemic Stroke +[16] 
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2007/08/06
Country/TerritoryBelgiumCanadaUnited States +[38] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesViiv Healthcare
China Registration ClassN/A

Develop Information

Active CompaniesHôpitaux Universitaires GenèveUniversity Of California San FranciscoGodecke Gmbh +[8] 
Inactive CompaniesGlaxosmithkline PlcWashington University School Of MedicinePfizer Inc +[10] 
Active IndicationsRejection of lung transplantationIschemic StrokePrimary Graft Dysfunction +[7] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Cognition DisordersInflammation +[9] 

Other Information

ATC CodeJ05AX09
Related LinksWikipediaDrugBankKEGG